Where does the combination of sorafenib and interferon in renal cell carcinoma stand?
- PMID: 19890962
- DOI: 10.1002/cncr.24688
Where does the combination of sorafenib and interferon in renal cell carcinoma stand?
Comment on
-
Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis.Cancer. 2010 Jan 1;116(1):57-65. doi: 10.1002/cncr.24685. Cancer. 2010. PMID: 19862815 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical